Europe withdraws Tavneos as AAV treatment and opens a gap for other complement inhibitors?

The withdrawal creates a notable gap in the treatment landscape for ANCA-associated vasculitis (AAV), a group of rare, potentially life-threatening autoimmune diseases in which the immune system attacks small blood vessels. The resulting inflammation can cause severe and irreversible organ damage, particularly to the kidneys.

Standard treatment relies heavily on immunosuppression and corticosteroids. Reducing long-term steroid exposure remains an important treatment goal because of the significant toxicities associated with chronic glucocorticoid use.

Tavneos had offered a targeted alternative. Its withdrawal therefore does more than remove one product from the European market: it potentially reopens a clinical opportunity that complement-focused drug developers have been pursuing for years.

What happened to Tavneos?

The European Commission formally revoked Tavneos’ EU marketing authorization on August 4, following a recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Tavneos had been approved in Europe in 2022 for adults with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the two most common forms of AAV, in combination with standard immunosuppressive treatment.

The regulatory concerns center on the ADVOCATE Phase III trial, which provided the pivotal evidence for the drug’s original approval.

According to the CHMP assessment, an ongoing review identified “serious breaches” of good clinical practice in the handling of primary endpoint data. Sponsor personnel had access to unblinded efficacy information after the initial database lock. Nine patients were subsequently re-adjudicated based on knowledge of treatment outcomes, after which the primary analysis changed from a non-significant to a statistically significant result for superiority at week 52.

The CHMP concluded that the pivotal study could no longer be considered reliable. It also cited reports of serious hepatic adverse events, including fatal cases of drug-induced liver injury and vanishing bile duct syndrome.

“On balance,” the CHMP concluded, there was no longer evidence that the benefits of Tavneos outweighed its risks, particularly in view of the serious hepatic risks.

A global regulatory problem

The European decision is part of a much broader regulatory reckoning around Tavneos. The drug had received approvals in Japan, the U.S., the EU and the UK between September 2021 and May 2022, but all four markets are now facing regulatory scrutiny over the ADVOCATE data and safety profile.

In the U.S., the FDA’s Center for Drug Evaluation and Research has formally proposed withdrawal. Amgen, which acquired ChemoCentryx for $3.7 billion in 2022 and inherited Tavneos, is opposing the withdrawal and has requested a public hearing. In July, the company submitted additional analyses, including a blinded re-adjudication of the ADVOCATE trial, arguing that the totality of evidence still supports the drug’s efficacy and benefit-risk profile.

Japan has issued a reporting order to Kissei, which holds the country’s marketing rights, concerning the handling of clinical trial results and other Tavneos-related matters. Meanwhile, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing whether the ADVOCATE data-integrity concerns alter the drug’s benefit-risk profile.

The outcome of the U.S. and Japanese proceedings remains open, but Europe has already taken the most definitive step: Tavneos is no longer authorized.

Could the vacuum benefit InflaRx?

One company that could potentially benefit from the changed landscape is InflaRx, Germany, although its candidates remain investigational and should not be viewed as direct replacements for Tavneos at this stage.

The Jena-based company is developing two complement-targeted approaches for AAV. Its lead AAV candidate izicopan is an oral inhibitor of C5a receptor 1 (C5aR1). This puts it at the same general molecular target as avacopan: Tavneos was designed to block the C5a receptor and thereby inhibit complement-driven inflammation.

InflaRx argues that izicopan has a differentiated pharmacological profile and is preparing a Phase II study in AAV. The company has already generated clinical data with the drug in other immune-mediated diseases.

InflaRx also has a second, complementary approach in vilobelimab, an antibody that directly targets the complement protein C5a rather than its receptor. The antibody has previously been investigated in AAV in two Phase II studies, according to the company, and InflaRx sees it as a potential candidate for further development in Phase III.

A Chinese partner, Staidson, is developing BDB-001, an anti-C5a antibody based on the vilobelimab technology. A Phase III AAV study is already underway in China following positive Phase I/II data.

The bigger picture

The Tavneos case illustrates both the promise and the vulnerability of targeted therapies in rare autoimmune diseases.

Avacopan was developed to address a fundamental problem in AAV: suppressing the disease without exposing patients to prolonged high-dose steroids. Its eventual regulatory downfall, however, is centered not on the underlying biological rationale but on the reliability of the clinical evidence used to establish efficacy and on safety concerns.

That distinction matters for the next generation of complement inhibitors. The withdrawal does not invalidate complement inhibition as a therapeutic strategy in AAV. Instead, it potentially raises the bar for demonstrating efficacy, safety and data integrity.

For developers such as InflaRx, that creates both an opportunity and a challenge. A market without Tavneos could increase the medical need for a targeted, steroid-sparing therapy. But any successor will need to establish its benefit-risk profile with a robust clinical package and unambiguous data.

In other words, Tavneos may have lost its European authorization, but the biological target it validated has not disappeared. The next question is whether another complement-directed therapy can turn that mechanism into a more durable regulatory and clinical success.